Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Creabilis Pulls In Corporate VC With €15M Series B

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott Biotech Ventures is the lead investor in a Series B fundraising for Creabilis to move its psoriasis candidate through Phase II.

You may also be interested in...



Mediolanum Acquires Phase II-Ready Cancer Vaccine From Italy’s Genovax

Italian life sciences seed capital firm Eporgen Venture has used a network of wealthy individuals in Italy to fund a group of new biotech companies, and has entered into its first transaction, selling Genovax’s potential cancer vaccine to Italian pharmaceutical company Mediolanum.

arGen-X Raises $37 Million To Advance Its Human Antibodies Into The Clinic

European biotech arGEN-X adds U.S VC firm OrbiMed as an investor as it raises $37 million in a Series B financing.

Anti-NGFs Advisory Committee Postponed As FDA Reviews New Information

The agency is assessing safety signals for the biologics, which are being developed for chronic pain.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel